Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

22 Feb 2021

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to T-cell and B-cell Immunology

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 33619368
DOI: 10.1038/s41591-021-01245-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myelomaPMID 33619368Read ↗

Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myelomaSemantic proximity Read ↗

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.Semantic proximity Read ↗

Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is LimitedSemantic proximity Read ↗

PD1+TIGIT+2B4+KLRG1+ cells might underlie T-cell dysfunction in patients treated with BCMA-directed CAR-T therapySemantic proximity Read ↗

Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myelomaSemantic proximity Read ↗

A simple and robust clinical manufacturing process for the ex-vivo expansion of autologous T cells genetically engineered to express an anti-BCMA chimeric antigen receptor (CAR) for the treatment of multiple myelomaSemantic proximity Read ↗

PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.Semantic proximity Read ↗

AT heterozygosity in a patient with multiple myeloma.Semantic proximity Read ↗

A novel mutation involving the carboxy terminal region of the FGFR3 gene in a multiple myeloma patient with t(4;14).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.